A comparison of common treatments for acute sinusitis that included an antibiotic and a topical steroid found neither more effective than placebo, according to a study in the December 5 issue of JAMA.
Acute sinusitis (sinus infection) is a common clinical problem with symptoms similar to other illnesses, and is often diagnosed and treated without clinical confirmation. Despite the clinical uncertainty as to a bacterial cause, antibiotic prescribing rates remain as high as 92 percent in the United Kingdom and 85 percent to 98 percent in the United States, according to background information in the article.
“Because there are no satisfactory studies of microbiological etiology from typical primary care patient practices, wide-scale overtreatment is likely occurring,” the authors write. Concerns about wide-spread antibacterial use include increasing antibiotic resistance in the community. Anti-inflammatory drugs such as topical steroids are also used as a treatment and may be beneficial, but there has been limited research.
Ian G. Williamson, M.D., of the University of Southampton, England, and colleagues conducted a double-blind randomized placebo-controlled trial to determine the effectiveness of the antibiotic amoxicillin and topical steroid budesonide in acute maxillary sinusitis (rhinosinusitis; inflammation of the nasal cavity and sinuses). The study included 240 adults with acute nonrecurrent sinusitis treated at 58 family practices between November 2001 and November 2005. Patients were randomized to 1 of 4 treatment groups: antibiotic and nasal steroid (500 mg of amoxicillin 3 times per day for 7 days and 200 ìg of budesonide in each nostril once per day for 10 days); placebo antibiotic and nasal steroid; antibiotic and placebo nasal steroid; placebo antibiotic and placebo nasal steroid.
The researchers found that the proportions of patients with symptoms lasting 10 or more days were 29 of 100 (29 percent) for amoxicillin vs. 36 of 107 (33.6 percent) for no amoxicillin; and 32 of 102 (31.4 percent) for topical budesonide vs. 33 of 105 (31.4 percent) for no budesonide. Secondary analysis suggested that nasal steroids were significantly more effective in patients with less severe symptoms at baseline.
“Our main conclusions are that among patients with the typical features of acute bacterial sinusitis, neither an antibiotic nor a topical steroid alone or in combination are effective in altering the symptom severity, the duration, or the natural history of the condition. Topical steroids are likely to be effective in those with such features but who have less severe symptoms at presentation to the physician,” the authors write.
Source: JAMA
Related stories:
Mimic molecules to protect against plague
Bacteria that cause pneumonic plague can evade our first-line defences, making it difficult for the body to fight infection. In fact, a signature of the plague is the lack of an inflammatory response. Now, scientists have discovered a way to protect against death following infection with plague bacteria, by using molecules that can mimic the pathogens. According to research published in the July issue of
Microbiology, these molecules make antibiotics more effective and can even be used to protect against other diseases.
Alligator blood may put the bite on antibiotic-resistant infections
Despite their reputation for deadly attacks on humans and pets, alligators are wiggling their way toward a new role as potential lifesavers in medicine, biochemists in Louisiana reported today at the 235th national meeting of the American Chemical Society. They described how proteins in gator blood may provide a source of powerful new antibiotics to help fight infections associated with diabetic ulcers, severe burns, and “superbugs” that are resistant to conventional medication.
Scientists uncover how superbug Staph aureus resists our natural defenses
Researchers at the University of Washington have uncovered how the bacterium Staphylococcus aureus, including the notorious MRSA (methicillin-resistant Staph aureus) “superbug” strains, resists our body's natural defenses against infection. The work, which was featured on the cover of the March 21 issue of
Science, could lead to new ways to fight the bacteria.
Synthetic peptoids hold forth promise for new antibiotics
Drug-resistant bacterial infections are a growing concern, and much research has been devoted to finding new classes of antibiotics to fight them.
Synthetic peptoids hold forth promise for new antibiotics
Drug-resistant bacterial infections are a growing concern, and much research has been devoted to finding new classes of antibiotics to fight them.
Best treatment identified to reduce deadly Staph infections
One type of over-the-counter product for topical wound care is more effective than others in killing methicillin-resistant Staphylococcus aureus bacteria, or MRSA, which is potentially deadly and in recent years has moved from its historic hospital setting to a much broader public concern.
Staph infections carry long-term risks
Patients who harbor the highly contagious bacterium causing staph infections can develop serious and sometimes deadly symptoms a year or longer after initial detection, a UC Irvine infectious disease researcher has found.
New antibiotic beats superbugs at their own game
The problem with antibiotics is that, eventually, bacteria outsmart them and become resistant. But by targeting the gene that confers such resistance, a new drug may be able to finally outwit them. Rockefeller University scientists tested the new drug, called Ceftobiprole, against some of the deadliest strains of multidrug-resistant Staphylococcus aureus (MRSA) bacteria, which are responsible for the great majority of staphylococcal infections worldwide, both in hospitals and in the community.